Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proellex extension study for uterine fibroids
NCT01069120Phase 3Terminated
- Sponsor
- Repros Therapeutics Inc.
- Start
- Apr 2009
- Primary completion
- Aug 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of telapristone in Uterine Fibroids (UF) (2 arms), sponsored by Repros Therapeutics Inc. Primary endpoint: Adverse Events and Serious Adverse Events at 8 months. Started Apr 2009; status: terminated.
02
Drugs
telapristone
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT01069120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01069120.